91 results about "Axon growth" patented technology

The present invention provides methods and compositions for enhancing regeneration and / or repair of neural tissue. One method include providing a nanoscale structured material at the site of injury, wherein the nanoscale structured material provides an environment that is permissive for regeneration of neural tissue and allows axon growth from a location on one side of a site of injury or barrier to a location on the other side of the site of injury or barrier. A second method includes introducing a composition comprising self-assembling peptides into the subject at the site of injury, wherein the peptides are amphiphilic peptides that comprise substantially equal proportions of hydrophobic and hydrophilic amino acids and are complementary and structurally compatible. A variety of compositions comprising a nanoscale structured material or precursor thereof, and an additional substance such as a regeneration promoting factor, are also provided. In certain embodiments of the invention the nanoscale structured material or precursor thereof comprises self-assembling peptides. The invention further provides compositions and methods for repair of an intervertebral disc, including nucleus pulpusos repair.

Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.

The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from Clostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. These new antagonists are a significant improvement over C3 compounds because they are 3-4 orders of magnitude more potent to stimulate axon growth on inhibitory substrates than recombinant C3. The invention further provides evidence that these compounds promote repair when applied to the injured mammalian central nervous system.

The invention relates to polypyrrole biological conductive hydrogel, as well as a preparation method and application thereof. The preparation method comprises the following steps; preparing carboxymethylchitosan hydrogel from carboxymethyl chitosan by using a crosslinking agent under a certain condition, and performing freeze-drying treatment; performing electrochemical synthesis on a pyrrole monomer to obtain polypyrrole, adding a dopant into the polypyrrole to perform modification and performing ball-milling and crushing to enable the particle size to be matched with the pore diameter of pores of the carboxymethylchitosan hydrogel; blending nerve growth factors into water, adding modified polypyrrole particles, stirring and dispersing uniformly, putting the carboxymethylchitosan hydrogel to enable the solution to be completely absorbed, adding water, vibrating, and completely swelling and balancing to obtain the polypyrrole biological conductive hydrogel. When the polypyrrole biological conductive hydrogel is applied to neural restoration, sustained release of neurotrophic factors can be completed, nerve cells can be subjected to certain electrical stimulation through bioelectrical or external electrical stimulation, proliferation and differentiation of the nerve cells are promoted through double effects of electric stimulation and neurotrophic factor induction, and nerve axon growth is guided.

The invention relates to promotion of a process for regeneration of an injured nerve using a plurality of guiding means, preferably a plurality of guiding fibres, presenting an in vivo biodegradability being such that at least a majority of said guiding means becomes essentially disintegrated by degradation (and / or dissolution) during a pre-contact period extending from application of the device at the injured nerve up to a first occurrence of a re-established (regenerated) contact between the ends of the injured nerve. During a post-contact period extending from the end of the pre-contact period and up to the end of the regeneration process, the disintegrated guiding means will provide no substantial axon growth guiding function and no substantial axon growth blocking effect.

This invention relates to the 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably such synthetic isomers, and pharmaceutical compositions containing such isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth and cell viability. Geranylgeranyl acetone is a known anti-ulcer drug used commercially and in clinical situations. GGA has also been shown to exert cytoprotective effects on a variety of organs, such as the eye, brain, and heart.

The invention relates to a conductive parallel fiber membrane which is capable of promoting rapid repair of peripheral nervous tissues and is connected to an extracellular matrix, wherein the thin film (the fiber membrane) can serve as a biofunctional nerve scaffold. The conductive parallel fiber membrane which is connected to the extracellular matrix and is of a core-shell structure is prepared by virtue of a three-step method, namely preparing parallel fibers through electrostatic spinning, covering conductive polypyrrole through electrochemical oxidation, and conducting human skin fibroblast culture and splitting cells by virtue of a triton x-100 / ammonia water mixed solution. According to the invention, the composite fiber membrane, by virtue of the parallel structure, can guide the growth of nerve fibers in a directional mode, by virtue of the extracellular matrix, adhesion of the nerve cells and axon thereof is improved, and by virtue of the conductive polymer (the conductive polypyrrole), the growth of the nerve axon is promoted through electric stimulation; and with a synergistic effect among the three means, the regeneration and repair of nerves are promoted. A preparation device adopted by the invention is simple and easy, simple to operate, wide in material source and low in cost; and the prepared nerve scaffold is good in biocompatibility and functionality, and the nerve scaffold is expected to be applied to clinical field in the future.

Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition. Mixtures of NgR and p75 are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to p75 and promoting axon regeneration.

The invention relates to a biological material used to recover hurt brain. Wherein, it uses transparent hyaluronic acid as raw material, guided by carbodiimide hydrochlorate (EDC), to use adipic acid adipoyl (ADH) to cross, to obtain the hyaluronic acid gel, as the carrier of graft antibody; and uses antibody solidification technique to graft the antibodies of axon growth restrain factor MAG, OMgp and Nogo-A to the hyaluronic acid gel, to be the antibody transfer system carrying special antibody and sensitive to pH value. The invention can be used to seal the never axon regeneration restrain factor of myelin and accelerate the regeneration of hurt brain organism.

The invention discloses nanoparticles loaded with therapeutic factors or neurotrophic factors. The nanoparticles are made of a high molecular material; the high molecular material is composed of biocompatible positively charged epsilon-polylysine and negatively charged heparin; the mass ratio of epsilon-polylysine to heparin ranges from 1:20 to 1:1; and average particle size grain diameter of the nanoparticles ranges from 100 to 400nm. The epsilon-polylysine-heparin nanoparticles are taken as carriers for loading of neurotrophic factors, and are high in biocompatibility, and stable in biochemical properties. The nanoparticles loaded with neurotrophic factors are capable of promoting cell axon growth effectively via sustained release.

Currently no therapies that provide either protection or restoration of neuronal function for adult onset neurodegenerative diseases such as Parkinson's disease exist. Many clinical efforts to provide such benefits by infusion of neurotropic factors have failed. An alternative approach such as viral construct transduction may be used to directly activate the intracellular signaling pathways that mediate neurotrophic effects and induce axon growth. Viral construct transduction of dopaminergic neurons with a constitutively active human form of the p70S6K gene—hp70S6K (CA)—was shown to induce axon regeneration from living dopaminergic cell bodies that had no living axons.

This invention relates, e.g., to a method for promoting CNS axon regeneration, comprising (1) inhibiting the expression or activity in a neuron of one or more of the members of the Krüppel-like transcription factor (KLF) family that suppress axon growth (e.g., KLF 1, 2, 3, 4, 5, 9, 12, 13, 14, 15 and / or 16), and / or (2) stimulating the expression or activity in a neuron of one or more of the members of the KLF family that promote axon growth (e.g., KLF 6 and / or 7).

Allylic compounds represented by the formula (I) are provided, wherein each of R1 to R8, m, n, A and X are as defined in the Specification. These compounds can inhibit Rho kinase, and can find utility in repair of damaged nerves in the central and peripheral nervous system by inducing axon growth and regeneration, and in the treatment by inhibition of Rho kinase in disease states in which Rho kinase is implicated. The compounds are relatively cell permeable and pharmaceutical compositions thereof can promote neurite growth and are also useful for the prevention of cell proliferation in malignant deseases.

Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent.

This invention relates to the 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably such synthetic isomers, and pharmaceutical compositions containing such isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth and cell viability. Geranylgeranyl acetone is a known anti-ulcer drug used commercially and in clinical situations. GGA has also been shown to exert cytoprotective effects on a variety of organs, such as the eye, brain, and heart.

The present invention provides MICAL and MICAL-Like polypeptides and polynucleotides. Also provided are methods that for identifying agents that affect axon growth and placement. Furthermore, provided herein are methods for affecting axon growth and placement.

The invention discloses application of miR-20a to preparation of a medicine for promoting nerve regeneration and repairing nerve injury, and further discloses application of the miR-20a to aspects ofpromoting DRG neuron axon regeneration and repairing peripheral nerve injury. The application is characterized by comprising the following processes: S1, the expression change of the miR-20a in DRG tissue after sciatic nerve injury of rats is detected; S2, the miR-20a is overexpressed in vitro to promote growth of DRG neuron axons; and S3, the miR-20a is overexpressed in vivo to promote growth ofthe DRG neuron axons. The miR-20a can participate in repairing of peripheral nerve injury by regulating growth of the DRG neuron axons, so that the important effect of microRNA (miRNA) in the nerve injury repair process can be better understood, and a new target is provided for treatment after nerve injury.

A robotic microfluidic incubator system has a thin transparent sidewall and close proximity of the embryo / oocyte / cultured cells to the sidewall allow close approach of a side view microscope with adequate focal length for mid to high power. This arrangement permits microscopic examination of multiple culture wells when arranged in rows (linear or along the circumference of a carousel). Manual or automated side to side movement of the linear well row, or rotation of the carousel, allows rapid inspection of the contents each well. Automated systems with video capability also allow remote inspection of wells by video connection or Internet connection, and automated video systems can record oft-hours inspections or time lapse development in culture (i.e. embryo cell division progression, or axon growth in neuron cell cultures).

This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

The invention discloses an MSCs (Mesenchymal stem cells) sourced schwann cell trophoblast type axon growth method of sensory neurone. The method comprises the following steps: S1, culturing P2-generation umbilical cord MSCs with umbilical cord wharton jelly of a newborn through an MSCs culture medium; S2, suspending the P2-generation umbilical cord MSCs through the MSCs culture medium; inoculatingto a recombinant human laminin and recombinant human vitronectin coated cell culture plate for culturing until the confluence reaches 60-70%; and preparing neuroepithelium pre-induced cell through aneural differentiation culture medium; S3, culturing P0-generation SCs with the neuroepithelium pre-induced cell through an SCs culture medium; and performing a subculture until P1 generation is obtained; S4, preparing an SCs trophoblast through P1-geneation SCs; and S5, preparing DRG (Dorsal root ganglion) sensory neurone cells; and performing co-culture through the SCs trophoblast and the DRG sensory neurone cells. According to the method, a new ideal is provided for cell therapy on nerve injury and repair of central nervous system.

A robotic microfluidic incubator system has a thin transparent sidewall and close proximity of the embryo / oocyte / cultured cells to the sidewall allow close approach of a side view microscope with adequate focal length for mid to high power. This arrangement permits microscopic examination of multiple culture wells when arranged in rows (linear or along the circumference of a carousel). Manual or automated side to side movement of the linear well row, or rotation of the carousel, allows rapid inspection of the contents each well. Automated systems with video capability also allow remote inspection of wells by video connection or Internet connection, and automated video systems can record oft-hours inspections or time lapse development in culture (i.e. embryo cell division progression, or axon growth in neuron cell cultures).

The invention provides PirB extracellular polypeptide which potentially treats central lesion. The polypeptide has an extracellular amino acid sequence of a paired immunoglobin-like receptor. The polypeptide segment can be massively expressed in escherichia coli and combined with myelin inhibiting factors MAG, Nogo-66 and OMgp in high affinity, so as to antagonize the bioactivity and function of PirB. The PEP provided by the invention can be effectively combined with myelin inhibiting factors MAG, Nogo-66 and OMgp so as to promote axon growth. The PEP provided by the invention can be massively prepared, is low in cost and high in activity, can be used for preparing medicines for treating various CNS (Central Nervous System) damages such as cerebral ischemia and anoxia, cerebral hemorrhage, cerebral trauma and spinal cord injury, and can effectively promote the regeneration of nervous tissues and neural functional recovery.

The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from Clostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. These new antagonists are a significant improvement over C3 compounds because they are 3-4 orders of magnitude more potent to stimulate axon growth on inhibitory substrates than recombinant C3. The invention further provides evidence that these compounds promote repair when applied to the injured mammalian central nervous system.

The present invention provides a method for identifying compounds which modulate the interaction of Nogo and Nogo receptor (NgR). The present invention also provides compounds that modulate the interaction of Nogo and Nogo receptor (NgR), the use of such compounds and compositions in the treatment or amelioration of conditions diseases or disorders, such as spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, ALS, Huntington's disease, Alzheimer's disease, Parkinson's disease, epilepsy, Schizophrenia or schizoaffective disorders.

The invention belongs to the technical field of medicines and particularly relates to a pharmaceutical composition. The pharmaceutical composition contains fasudil hydrochloride and nucleotide derivatives, wherein the content of the nucleotide derivatives in the pharmaceutical composition is 0.1-25 times of the content of the fasudil hydrochloride. The invention also discloses a preparation method and application of the pharmaceutical composition. The pharmaceutical composition has the effects of improving the activity of myosin light chain phosphatase to expand blood vessels, reducing the tensions of endothelial cells, improving microcirculation of brain tissues, protecting nerve to avoid apoptosis and promoting nerve regeneration so as to prevent and reduce cerebral vasospasm caused by various reasons and selectively expand the spasmodic blood vessels; and the pharmaceutical composition can also be used for inhibiting the damage of cerebral neurons, promoting the axon growth of neural cells and relieving the inflammatory response of involved brain cells.

The invention provides a DNA vaccine for promoting regeneration and functional rehabilitation of nerves of a central system. The vaccine consists of antigen genes and eukaryon expression vectors, wherein the antigen genes are fusion genes which are formed by linearly connecting gene fragments in the LRR structure field of the coding LINGO-1, gene fragments in the EGFL structure field of the coding TN-R and gene fragments of the 1011st to the 1271st amino acid of the coding neurocan in sequence; and two of the gene fragments are connected by the DNA sequences coding three alanine. The DNA vaccine can express the fusion genes of the LRR structure field of the LINGO-1, the EGFL structure field of the TN-R and the 1011st to the 1271st amino acid of the neurocan, stimulate the human body to generate various antibodies of the nerve regeneration inhibiting factor, resist the activity of the axon growth inhibiting factor, and provide a good microenvironment for the regeneration and the functional rehabilitation of the nerves of the central system.

The invention discloses a preparation method and application of a bionic silicified collagen material. The preparation method disclosed by the invention comprises the step of soaking ACE collagen in a pretreatment solution to obtain a bionic silicified collagen material, wherein the pretreatment solution is composed of choline chloride and an orthosilicic acid solution. The bionic silicified collagen material constructed by the invention has good physical and chemical properties, and can promote the growth of peripheral sensory nerve axons and activate a sensory nerve mTOR signal channel to secrete Semaphorins 3A.